106 related articles for article (PubMed ID: 12065876)
1. mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer.
Paradiso A; Ranieri G; Simone G; Silvestris N; Costa A; De Lena M; Leone A; Vallejo C; Lacava J
Oncology; 2002; 62(3):278-85. PubMed ID: 12065876
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
[TBL] [Abstract][Full Text] [Related]
3. Expression of mdm2 and p53 in epithelial neoplasms of the colorectum.
Hao XP; Günther T; Roessner A; Price AB; Talbot IC
Mol Pathol; 1998 Feb; 51(1):26-9. PubMed ID: 9624416
[TBL] [Abstract][Full Text] [Related]
4. Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer.
Paradiso A; Simone G; Lena MD; Leone B; Vallejo C; Lacava J; Dellapasqua S; Daidone MG; Costa A
Br J Cancer; 2001 Mar; 84(5):651-8. PubMed ID: 11237386
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas.
Valassiadou KE; Stefanaki K; Tzardi M; Datseris G; Georgoulias V; Melissas J; Tsiftsis DD; Delides G; Kanavaros P
Anticancer Res; 1997; 17(4A):2571-6. PubMed ID: 9252682
[TBL] [Abstract][Full Text] [Related]
6. Expression of p53 and mdm2 mRNA and protein in colorectal carcinomas.
Broll R; Stark A; Windhövel U; Best R; Strik MW; Schimmelpenning H; Schwandner O; Kujath P; Bruch HP; Duchrow M
Eur J Cancer; 1999 Jul; 35(7):1083-8. PubMed ID: 10533452
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer.
Baekelandt M; Kristensen GB; Nesland JM; Tropé CG; Holm R
J Clin Oncol; 1999 Jul; 17(7):2061. PubMed ID: 10561259
[TBL] [Abstract][Full Text] [Related]
8. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
Liang JT; Huang KC; Cheng YM; Hsu HC; Cheng AL; Hsu CH; Yeh KH; Wang SM; Chang KJ
Int J Cancer; 2002 Feb; 97(4):451-7. PubMed ID: 11802206
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
[TBL] [Abstract][Full Text] [Related]
10. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients.
Paradiso A; Simone G; Petroni S; Leone B; Vallejo C; Lacava J; Romero A; Machiavelli M; De Lena M; Allegra CJ; Johnston PG
Br J Cancer; 2000 Feb; 82(3):560-7. PubMed ID: 10682666
[TBL] [Abstract][Full Text] [Related]
11. MDM2/p53 protein expression in the development of colorectal adenocarcinoma.
Abdel-Fattah G; Yoffe B; Krishnan B; Khaoustov V; Itani K
J Gastrointest Surg; 2000; 4(1):109-14. PubMed ID: 10631371
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis and cell-cycle regulatory proteins in colorectal carcinoma: relationship to tumour stage and patient survival.
Elkablawy MA; Maxwell P; Williamson K; Anderson N; Hamilton PW
J Pathol; 2001 Aug; 194(4):436-43. PubMed ID: 11523051
[TBL] [Abstract][Full Text] [Related]
13. P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival.
Kasper HU; Schneider-Stock R; Mellin W; Günther T; Roessner A
Pathol Res Pract; 1999; 195(12):815-20. PubMed ID: 10631716
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
Johnston PG; Benson AB; Catalano P; Rao MS; O'Dwyer PJ; Allegra CJ
J Clin Oncol; 2003 Mar; 21(5):815-9. PubMed ID: 12610179
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of apoptosis and apoptosis-associated proteins in salivary gland adenoid cystic carcinoma.
Jia L; Esguerra RL; Tang X; Yin H; Sakamoto K; Okada N; Takagi M
Pathol Int; 2004 Apr; 54(4):217-23. PubMed ID: 15028021
[TBL] [Abstract][Full Text] [Related]
17. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma.
Jahnson S; Karlsson MG
Cancer; 2000 Aug; 89(3):619-29. PubMed ID: 10931462
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to 5-fluorouracil.
Kamoshida S; Matsuoka H; Shiogama K; Matsuyama A; Shimomura R; Inada K; Maruta M; Tsutsumi Y
Pathol Int; 2004 Aug; 54(8):564-75. PubMed ID: 15260847
[TBL] [Abstract][Full Text] [Related]
19. The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer.
Ahmed IA; Kelly SB; Anderson JJ; Angus B; Challen C; Lunec J
Colorectal Dis; 2008 May; 10(4):344-51. PubMed ID: 17949449
[TBL] [Abstract][Full Text] [Related]
20. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
